NovaBay Pharmaceuticals Inc (NYSE MKT LLC:NBY)

0.6251
Delayed Data
As of Apr 24
 -0.0049 / -0.78%
Today’s Change
0.42
Today|||52-Week Range
1.30
-0.78%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$39.1M

Company Description

NovaBay Pharmaceuticals, Inc. engages in developing compounds to address the unmet therapeutic needs. It operates through the following segments: Dermatology, Ophthalmology, Urology, Wound Care, and Others. The Dermatology segment includes all aspects of its business around the dermatology arena including the collaboration with Galderma and their impetigo clinical trial. The Ophthalmology segment includes Avenova and its clinical trial on ophthalmology which it was conducting on its own. The Urology segment covers its urinary catheter encrustation and blockage (UCBE) trials. The Wound Care segment encompasses the business around its NeutroPhase product. The Others segment are immaterial and are shown as an aggregate. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.

Contact Information

NovaBay Pharmaceuticals, Inc.
5980 Horton Street
Emeryville California 94608
P:(510) 899-8800
Investor Relations:
(510) 899-8809

Employees

Shareholders

Individual stakeholders24.94%
Other institutional2.75%
Mutual fund holders2.12%

Top Executives

Ramin NajafiPresident, Chief Executive Officer & Director
Thomas J. PaulsonCFO, CAO, Secretary & Treasurer
Ken KrantzVice President-Medical Affairs
Roy J. WuSenior VP-Business & Corporate Development
Russell A. HoonVice President-Advanced Wound Care Unit

To view my watchlist

Not a member yet?

Sign up now for a free account